The achievement of that goal in India, which ranks third in obesity numbers after the US and China, will shatter the record ...

Novo Nordisk launches Wegovy in India, a once-weekly weight-loss injection shown to aid obesity treatment and reduce heart ...

CHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients ...

The trial assessed the effect of the treatments on kidney outcomes for prevention of progression of kidney disease and risk of kidney and CV mortality in people with type 2 diabetes and CKD ...

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal. The Danish ...

We speak to Novo Nordisk's Stephen Gough about the company’s drive to tackle complications of type 2 diabetes such as chronic kidney disease ...

Novo Nordisk said on Monday the European drugs regulator will allow a label update for its diabetes drug Ozempic to include a ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. While Novo lost share to Eli Lilly's once-weekly Trulicity, Ozempic and Rybelsus ...

Novo Nordisk has introduced Wegovy, a once-weekly weight loss injection, in India. The drug aims to manage obesity and reduce ...

Novo Nordisk has officially launched its anti-obesity drug Wegovy in India ahead of patent expiry. This move aims to tackle rising obesity rates while facing competition from rival drugs.

Danish pharma giant Novo Nordisk’s announcement comes months after launch of another top selling obesity drug Mounjaro in ...